Here's a connection you might not have made: the war disrupting oil tankers in the Strait of Hormuz could soon make the plastic bag holding your IV antibiotics more expensive. It's not a direct line from battleship to bedside, but analysts tracking the supply chain crunch say it's a real one, and it's moving faster than you might think.

The United States and Israel launched coordinated strikes across Iran on Feb. 28, and the conflict has now stretched into its 25th day with no clear end in sight. Iran has signaled it's prepared to shut down the Strait of Hormuz indefinitely, and maritime authorities have raised the threat level in the Gulf to critical. Oil markets are already reacting, with Brent crude surging past $100 a barrel. But the ripple effects go far beyond the gas pump.

The Petrochemical Link to Your Medicine Cabinet

Strikes on Gulf refineries have set off a chain reaction, according to David Weeks, supply chain lead at Moody's. "These facilities produce key derivatives such as naphtha and methanol, which are important inputs for industries including pharmaceuticals," Weeks told MarketDash.

Think of naphtha as the stuff that becomes your medicine's packaging, and methanol as a solvent used in making the active drug ingredients themselves. It's the hidden plumbing of the medical world.

The numbers are starting to reflect the strain. An estimated 18% of global methanol capacity has been affected by the Hormuz disruption, with U.S. prices up 18% since the conflict began, according to S&P Global Energy CERA data. Meanwhile, the profit margin for turning naphtha into industrial raw materials is at its highest point since early 2023, according to commodity trading house Alkagesta. When the middlemen are making bank, you know there's a squeeze happening upstream.

What's Actually at Risk in Hospitals

So what does this mean for you or a loved one in a hospital? The products most directly in the crosshairs are the utterly mundane, utterly essential consumables you encounter in virtually every stay: the plastic bags for IV antibiotics and cancer drugs, the tubing that connects them, the stoppers on medication vials, and the sterile wrapping around surgical instruments.

Kaitlyn Huissen, Vice President of Supply Chain Intelligence at Exiger, calls these items the earliest and most underappreciated pressure point. "Treatment can be constrained even when the drug itself is available," she said.

Based on Exiger's modelling, a petrochemical disruption like this typically takes two to four weeks to reach the factories making medical inputs. Hospitals then feel the impact closer to one inventory cycle later—generally 30 to 60 days—primarily through higher prices or suppliers starting to ration who gets what.

"This doesn't hit overnight, but it moves on a weeks, not months timeline, which is faster than most expect," Huissen said. It's the financial version of a slow-moving wave; you see it coming, but you can't really stop it from reaching shore.

How the Costs Pile Up: Freight and Insurance

It's not just the raw materials getting pricier. Getting anything through a war zone costs more. Freight and insurance costs are already rising.

War-risk premiums for shipping, which are typically a tiny fraction of a voyage's value, could double or triple, according to Weeks. On a $100 million vessel, that could mean an extra $1 million per trip. That's a cost that eventually gets baked into the price of everything on board, including medical supplies.

"There are a wide range of rates which change on an hourly basis as the situation evolves," said Rebekah Khew, Director at Vivace Insurance Partners Asia Pacific and a former Lloyd's underwriter. "Some cargo owners with shipments destined for ports within the Persian Gulf are considering discharging at ports outside the Strait, such as Dibba, followed by inland transit to final destination."

In other words, companies are already plotting complicated and expensive detours. Every rerouted truck or extra day at sea adds to the final bill.

Stocks in Focus

The stock market is a discounting machine, and it's already starting to price in these risks for companies that make the affected supplies. Here's a look at some notable names and how they've fared over the past turbulent month.

Note: The stocks mentioned represent a non-exhaustive list of companies potentially impacted by these developments.

How Long Will This Last?

This is the million-dollar question. The impact so far is about cost and complexity, not yet about empty shelves in operating rooms. But analysts warn that buffers are finite.

"If disruptions in the Gulf persist, cost pressures could broaden across supply chains," Weeks said.

Huissen echoed that, noting the safety nets in the system can only stretch so far. "If disruption persists, buffers begin to erode and operational workarounds lose effectiveness. That's when underlying vulnerabilities start to surface in availability and patient care," she said.

For American hospitals and patients already dealing with high healthcare costs, the immediate risk isn't a sudden drug shortage. It's a quieter, slower squeeze—a lagged increase in the price of all the mundane, plastic-and-rubber stuff that modern medicine runs on. That bill could start arriving in the coming weeks.